Planta Med 2011; 77(14): 1582-1589
DOI: 10.1055/s-0030-1270955
Biological and Pharmacological Activity
Original Papers
© Georg Thieme Verlag KG Stuttgart · New York

Pharmacological Properties of Myrtacine® and Its Potential Value in Acne Treatment

Christel Fiorini-Puybaret1 , Marie-Françoise Aries2 , Bernard Fabre1 , Stelianos Mamatas3 , Joëlle Luc4 , Arnaud Degouy2 , Marco Ambonati5 , Carine Mejean5 , Florence Poli6
  • 1Laboratoire des Produits Végétaux, Institut de Recherche Pierre Fabre, Centre de R & D Pierre Fabre 3, Toulouse, France
  • 2Laboratoire de Pharmacologie Cellulaire, Pierre Fabre Dermocosmétique, Centre de R & D Pierre Fabre 3, Toulouse, France
  • 3Institut de Recherche Pierre Fabre, Centre de R & D Pierre Fabre 3, Toulouse, France
  • 4Laboratoire de Bactériologie, Pierre Fabre Dermocosmétique, Vigoulet, France
  • 5Laboratoires Pierre Fabre Dermocosmétique, Les Cauquillous, Lavaur, France
  • 6Cabinet de Dermatologie, Paris, France
Further Information

Publication History

received Sept. 30, 2010 revised February 25, 2011

accepted March 9, 2011

Publication Date:
30 March 2011 (online)

Preview

Abstract

This study aimed at evaluating the antiproliferative, antibacterial, and anti-inflammatory properties of an ethanolic myrtle extract (Myrtacine®) in vitro, characterising its potential active compounds (myrtucommulones A and B’) by structural analysis, and evaluating their biological activity. Antiproliferative activity was assessed by the BrdU incorporation assay in HaCat keratinocytes and inhibitory and bactericidal activities against P. acnes strains by measuring the minimal inhibitory concentration (MIC) and D value. Anti-inflammatory effect was evaluated by measuring 6-keto-prostaglandin F1α and [3H]‐arachidonic acid metabolite production in keratinocytes stimulated for inflammation. Myrtacine® inhibited keratinocyte proliferation by 27 % and 76 % at 1 and 3 µg/mL, respectively (p < 0.001). A comparable effect, though less marked, was observed with 5 µg/mL myrtucommulones A and B’ (−36 % and −28 %, respectively). Myrtacine® inhibited erythromycin-sensible and ‐resistant P. acnes strains growth with MICs of 4.9 µg/mL and 2.4 µg/mL, respectively. Myrtucommulone B’ and myrtucommulone A displayed a similar inhibitory activity against both strains (for both strains, MIC = 1.2 µg/mL and about 0.5 µg/mL, respectively). At 3 and 10 µg/mL, Myrtacine® significantly decreased all metabolite production from cyclooxygenase (81 % and 107 %, p < 0.0001) and lipoxygenase (52 % and 95 %, p < 0.001) pathways. Finally, Myrtacine® exhibited a concentration-dependent anti-lipase activity at 100 µg/mL and 1 mg/mL, as it decreased lipase activity by respectively 53 % and 100 % (p < 0.01 for both). In conclusion, in vitro, Myrtacine® demonstrated antiproliferative, antibacterial, and anti-inflammatory properties that may be of value to exert a global action in the treatment of acne lesions.

References

Dr. Christel Fiorini-Puybaret

Laboratoire des Produits Végétaux
Institut de Recherche Pierre Fabre
Centre de R & D Pierre Fabre 3

Avenue Hubert Curien – BP 13562

31035 TOULOUSE Cedex 1

France

Phone: +33 5 34 50 60 00

Fax: +33 5 34 50 50 00

Email: christel.fiorini@pierre-fabre.com